261 related articles for article (PubMed ID: 24067381)
21. Myositis-related autoantibody profile and clinical characteristics stratified by anti-cytosolic 5'-nucleotidase 1A status in connective tissue diseases.
Diederichsen LP; Iversen LV; Nielsen CT; Jacobsen S; Hermansen ML; Witting N; Cortes R; Korsholm SS; Krogager ME; Friis T
Muscle Nerve; 2023 Jul; 68(1):73-80. PubMed ID: 37177880
[TBL] [Abstract][Full Text] [Related]
22. Inclusion body myositis: update.
Lahouti AH; Amato AA; Christopher-Stine L
Curr Opin Rheumatol; 2014 Nov; 26(6):690-6. PubMed ID: 25215417
[TBL] [Abstract][Full Text] [Related]
23. Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis.
Amlani A; Choi MY; Tarnopolsky M; Brady L; Clarke AE; Garcia-De La Torre I; Mahler M; Schmeling H; Barber CE; Jung M; Fritzler MJ
Front Immunol; 2019; 10():745. PubMed ID: 31024569
[No Abstract] [Full Text] [Related]
24. Ongoing developments in sporadic inclusion body myositis.
Machado PM; Ahmed M; Brady S; Gang Q; Healy E; Morrow JM; Wallace AC; Dewar L; Ramdharry G; Parton M; Holton JL; Houlden H; Greensmith L; Hanna MG
Curr Rheumatol Rep; 2014 Dec; 16(12):477. PubMed ID: 25399751
[TBL] [Abstract][Full Text] [Related]
25. Inclusion Body Myositis and Neoplasia: A Narrative Review.
Damian L; Login CC; Solomon C; Belizna C; Encica S; Urian L; Jurcut C; Stancu B; Vulturar R
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806366
[TBL] [Abstract][Full Text] [Related]
26. Novel serology testing for sporadic inclusion body myositis: disease-specificity and diagnostic utility.
Herbert MK; Pruijn GJ
Curr Opin Rheumatol; 2015 Nov; 27(6):595-600. PubMed ID: 26285103
[TBL] [Abstract][Full Text] [Related]
27. 272nd ENMC international workshop: 10 Years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16-18 June 2023, Hoofddorp, The Netherlands.
Lilleker JB; Naddaf E; Saris CGJ; Schmidt J; de Visser M; Weihl CC;
Neuromuscul Disord; 2024 Apr; 37():36-51. PubMed ID: 38522330
[TBL] [Abstract][Full Text] [Related]
28. [Pathogenesis of inclusion body myositis: autoimmune or degenerative disease?].
Uruha A; Nishino I
Brain Nerve; 2013 Nov; 65(11):1291-8. PubMed ID: 24200607
[TBL] [Abstract][Full Text] [Related]
29. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis.
Pluk H; van Hoeve BJ; van Dooren SH; Stammen-Vogelzangs J; van der Heijden A; Schelhaas HJ; Verbeek MM; Badrising UA; Arnardottir S; Gheorghe K; Lundberg IE; Boelens WC; van Engelen BG; Pruijn GJ
Ann Neurol; 2013 Mar; 73(3):397-407. PubMed ID: 23460448
[TBL] [Abstract][Full Text] [Related]
30. Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.
Yeker RM; Pinal-Fernandez I; Kishi T; Pak K; Targoff IN; Miller FW; Rider LG; Mammen AL;
Ann Rheum Dis; 2018 May; 77(5):714-719. PubMed ID: 29363513
[TBL] [Abstract][Full Text] [Related]
31. Positive Cytosolic 5-Nucleotidase 1A Antibodies in Motor Neuron Disease.
Assadi RK; Manousakis G
J Clin Neuromuscul Dis; 2020 Sep; 22(1):50-52. PubMed ID: 32833724
[TBL] [Abstract][Full Text] [Related]
32. Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus.
Rietveld A; van den Hoogen LL; Bizzaro N; Blokland SLM; Dähnrich C; Gottenberg JE; Houen G; Johannsen N; Mandl T; Meyer A; Nielsen CT; Olsson P; van Roon J; Schlumberger W; van Engelen BGM; Saris CGJ; Pruijn GJM
Front Immunol; 2018; 9():1200. PubMed ID: 29922285
[TBL] [Abstract][Full Text] [Related]
33. [Sporadic Inclusion Body Myositis and Autoantibodies].
Yamashita S; Ando Y
Brain Nerve; 2018 Apr; 70(4):449-457. PubMed ID: 29632292
[TBL] [Abstract][Full Text] [Related]
34. Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis.
Tawara N; Yamashita S; Zhang X; Korogi M; Zhang Z; Doki T; Matsuo Y; Nakane S; Maeda Y; Sugie K; Suzuki N; Aoki M; Ando Y
Ann Neurol; 2017 Apr; 81(4):512-525. PubMed ID: 28318044
[TBL] [Abstract][Full Text] [Related]
35. Exploring challenges in the management and treatment of inclusion body myositis.
Skolka MP; Naddaf E
Curr Opin Rheumatol; 2023 Nov; 35(6):404-413. PubMed ID: 37503813
[TBL] [Abstract][Full Text] [Related]
36. Atypical presentations of inclusion body myositis: Clinical characteristics and long-term outcomes.
Alamr M; Pinto MV; Naddaf E
Muscle Nerve; 2022 Dec; 66(6):686-693. PubMed ID: 36052422
[TBL] [Abstract][Full Text] [Related]
37. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis.
Askanas V; Engel WK
Curr Opin Rheumatol; 1998 Nov; 10(6):530-42. PubMed ID: 9812213
[TBL] [Abstract][Full Text] [Related]
38. Inclusion body myositis.
Greenberg SA
Curr Opin Rheumatol; 2011 Nov; 23(6):574-8. PubMed ID: 21885973
[TBL] [Abstract][Full Text] [Related]
39. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis.
Tasca G; Monforte M; De Fino C; Kley RA; Ricci E; Mirabella M
Muscle Nerve; 2015 Dec; 52(6):956-62. PubMed ID: 25808807
[TBL] [Abstract][Full Text] [Related]
40. Anti-cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis.
Paul P; Liewluck T; Ernste FC; Mandrekar J; Milone M
Muscle Nerve; 2021 Apr; 63(4):490-496. PubMed ID: 33373040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
